Arch Biopartners (TSXV:ARCH) Receivables Turnover : 0.00 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Arch Biopartners's Revenue for the three months ended in Dec. 2023 was C$0.00 Mil. Arch Biopartners's average Accounts Receivable for the three months ended in Dec. 2023 was C$0.00 Mil.

Arch Biopartners Receivables Turnover Historical Data

The historical data trend for Arch Biopartners's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Receivables Turnover Chart

Arch Biopartners Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Receivables Turnover

Get a 7-Day Free Trial

Arch Biopartners Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Arch Biopartners's Receivables Turnover

For the Biotechnology subindustry, Arch Biopartners's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Biopartners's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Receivables Turnover falls into.

Arch Biopartners Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Arch Biopartners's Receivables Turnover for the fiscal year that ended in Sep. 2023 is calculated as

	Receivables Turnover (A: Sep. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Sep. 2023 )	/ (	(Accounts Receivable (A: Sep. 2022 )	+	Accounts Receivable (A: Sep. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Arch Biopartners's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Sep. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Arch Biopartners (TSXV:ARCH) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Arch Biopartners Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners (TSXV:ARCH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.